Literature DB >> 4574207

Preliminary clinical trials with oxamniquine, a new antischistosomal agent.

N Katz, J Pellegrino, E Grinbaum, A Chaves, F Zicker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4574207

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN： 0036-4665            Impact factor:   1.846


× No keyword cloud information.
  4 in total

1.  Experimental chemotherapy of schistosomiasis mansoni. XIII. Activity of praziquantel, an isoquinoline-pyrazino derivative, on mice, hamsters and Cebus monkeys.

Authors:  J Pellegrino; F F Lima-Costa; M A Carlos; R T Mello
Journal:  Z Parasitenkd       Date:  1977-07-21

2.  Independent origins of loss-of-function mutations conferring oxamniquine resistance in a Brazilian schistosome population.

Authors:  Frédéric D Chevalier; Winka Le Clec'h; Nina Eng; Anastasia R Rugel; Rafael Ramiro de Assis; Guilherme Oliveira; Stephen P Holloway; Xiaohang Cao; P John Hart; Philip T LoVerde; Timothy J C Anderson
Journal:  Int J Parasitol       Date:  2016-04-09       Impact factor: 3.981

3.  Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening.

Authors:  Nuha R Mansour; Quentin D Bickle
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

4.  Oxamniquine resistance alleles are widespread in Old World Schistosoma mansoni and predate drug deployment.

Authors:  Frédéric D Chevalier; Winka Le Clec'h; Marina McDew-White; Vinay Menon; Meghan A Guzman; Stephen P Holloway; Xiaohang Cao; Alexander B Taylor; Safari Kinung'hi; Anouk N Gouvras; Bonnie L Webster; Joanne P Webster; Aidan M Emery; David Rollinson; Amadou Garba Djirmay; Khalid M Al Mashikhi; Salem Al Yafae; Mohamed A Idris; Hélène Moné; Gabriel Mouahid; P John Hart; Philip T LoVerde; Timothy J C Anderson
Journal:  PLoS Pathog       Date:  2019-10-25       Impact factor: 6.823
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.